IQVIA Holdings Inc. (IQV)
| Market Cap | 45.24B +26.5% |
| Revenue (ttm) | 17.31B +8.8% |
| Net Income | 1.39B +8.7% |
| EPS | 8.25 +13.0% |
| Shares Out | 164.80M |
| PE Ratio | 33.26 |
| Forward PE | 19.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,365,400 |
| Open | 276.89 |
| Previous Close | 275.15 |
| Day's Range | 274.32 - 281.24 |
| 52-Week Range | 154.50 - 284.50 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 311.89 (+13.61%) |
| Earnings Date | Oct 27, 2026 |
About IQV
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers ... [Read more]
Financial Performance
In 2025, IQVIA Holdings's revenue was $16.31 billion, an increase of 5.87% compared to the previous year's $15.41 billion. Earnings were $1.36 billion, a decrease of -0.95%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for IQV stock is "Strong Buy." The 12-month stock price target is $311.89, which is an increase of 13.61% from the latest price.
News
Iqvia price target raised to $307 from $288 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Iqvia (IQV) to $307 from $288 and keeps a Buy rating on the shares. The firm updated its model…
Iqvia price target raised to $346 from $329 at Truist
Truist analyst Jailendra Singh raised the firm’s price target on Iqvia (IQV) to $346 from $329 and keeps a Buy rating on the shares. The company reported strong Q3 results…
Iqvia price target raised to $310 from $290 at Evercore ISI
Evercore ISI raised the firm’s price target on Iqvia (IQV) to $310 from $290 and keeps an Outperform rating on the shares.
Iqvia price target raised to $325 from $295 at JPMorgan
JPMorgan raised the firm’s price target on Iqvia (IQV) to $325 from $295 and keeps an Overweight rating on the shares. The firm views the company’s Q3 report as a…
Iqvia price target raised to $328 from $324 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Iqvia (IQV) to $328 from $324 and keeps an Outperform rating on the shares.
Iqvia price target raised to $328 from $324 at Baird
Baird raised the firm’s price target on Iqvia (IQV) to $328 from $324 and keeps an Outperform rating on the shares.
IQVIA Holdings Earnings Call Transcript: Q3 2026
Q3 revenue, adjusted EBITDA and adjusted EPS exceeded guidance, with organic growth accelerating and R&D bookings reaching a four-year high. FY2026 guidance was raised; AI adoption, improving demand and stronger win rates supported momentum.
IQVIA Holdings Earnings release: Q3 2026
IQVIA Holdings released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
IQVIA Holdings Slides: Q3 2026
IQVIA Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 27, 2026.
IQVIA Holdings Quarterly report: Q3 2026
IQVIA Holdings has published its Q3 2026 quarterly earnings report on October 27, 2026.
Iqvia reports Q3 adjusted EPS $3.34, consensus $3.28
Reports Q3 revenue $4.428B, consensus $4.37B. “IQVIA (IQV) delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the high end of our expectations,” sai...
IQVIA Reports Third-Quarter 2026 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
Iqvia price target raised to $303 from $276 at Stifel
Stifel raised the firm’s price target on Iqvia (IQV) to $303 from $276 and keeps a Buy rating on the shares. The firm, which expects Iqvia to outperform consensus expectations…
Iqvia selects Veeva clinical operations applications
IQVIA (IQV) and Veeva Systems (VEEV) announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will…
IQVIA Selects Veeva Clinical Operations Applications
RESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, ...
Iqvia price target raised to $305 from $280 at BofA
BofA raised the firm’s price target on Iqvia (IQV) to $305 from $280 and keeps a Buy rating on the shares. The life science tools sector has further re-rated since…
Iqvia launches Iqvia Life Science Models
Iqvia (IQV) introduced Iqvia Life Science Models to help predict clinical trial outcomes. Iqvia Life Science Models are a suite of purpose-built models for life sciences, combining Iqvia’s proprietary...
Iqvia launches Iqvia Explorer
Iqvia (IQV) introduced Iqvia Explorer to help customers make better-informed commercial decisions. Iqvia Explorer turns complex, one-time analytics projects into an always-on commercial intelligence c...
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
Iqvia price target raised to $300 from $275 at Mizuho
Mizuho raised the firm’s price target on Iqvia (IQV) to $300 from $275 and keeps an Outperform rating on the shares. The firm adjusted targets in the healthcare facilities and…
Iqvia price target raised to $300 from $275 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Iqvia (IQV) to $300 from $275 and keeps an Overweight rating on the shares. The firm adjusted targets in the…
Iqvia resumed with a Buy at UBS
UBS resumed coverage of Iqvia (IQV) with a Buy rating and $345 price target The firm’s channel checks and survey results suggest Iqvia is gaining market share. The company is…
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
Iqvia price target raised to $319 from $247 at RBC Capital
RBC Capital raised the firm’s price target on Iqvia (IQV) to $319 from $247 and keeps an Outperform rating on the shares. The company’s 20 novel drug approvals in Q3,…